Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fortrea Holdings Inc. ( (FTRE) ) has provided an announcement.
On June 11, 2025, Fortrea Holdings Inc. announced the adoption of a limited-duration stockholder rights plan, effective immediately, to protect the interests of its stockholders amidst significant dislocation in its stock trading price. The plan, which expires on June 10, 2026, aims to ensure fair treatment in takeover scenarios and prevent hostile acquisitions without appropriate premiums. It allows stockholders to purchase additional shares at a discount if any entity acquires 10% or more of Fortrea’s common stock, encouraging potential acquirers to engage directly with the Board.
The most recent analyst rating on (FTRE) stock is a Hold with a $21.00 price target. To see the full list of analyst forecasts on Fortrea Holdings Inc. stock, see the FTRE Stock Forecast page.
Spark’s Take on FTRE Stock
According to Spark, TipRanks’ AI Analyst, FTRE is a Neutral.
Fortrea Holdings Inc. presents a complex investment case with significant financial and operational challenges. The most notable factors include negative profitability and high leverage, which weigh heavily on the stock’s outlook. While there are positive initiatives in pipeline management and cost reduction, these are overshadowed by the financial strain from goodwill impairment. Technical indicators and valuation further contribute to a cautious stance.
To see Spark’s full report on FTRE stock, click here.
More about Fortrea Holdings Inc.
Fortrea Holdings Inc. (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. The company partners with biopharmaceutical, biotechnology, medical device, and diagnostic companies to drive healthcare innovation and accelerate life-changing therapies to patients. Fortrea offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over three decades of experience across more than 20 therapeutic areas.
Average Trading Volume: 2,973,078
Technical Sentiment Signal: Sell
Current Market Cap: $489.6M
For detailed information about FTRE stock, go to TipRanks’ Stock Analysis page.